Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Zacks.com on MSN11d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekVertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
Vertex Pharma has chosen the three-drug combination it intends to submit for approval later this year for cystic fibrosis, in a bid to add another product to its stable. The US company has plumped ...
Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback